Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
- Status
- AVAILABLE
- Phase
- N/A
Clinical Trials Related to daraxonrasib
Related studies linked through entity extraction aliases.
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Status
- RECRUITING
- Phase
- PHASE3
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Status
- RECRUITING
- Phase
- PHASE3
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2